Posted

0 replies · 0 reposts · 2 likes

After approximately four months, they are talking about hantavirus again. Check out the following article: "Hantavirus, cause of Gene Hackman’s wife’s death, kills three in California" Source: https://www.msn.com/en-us/health/health-news/hantavirus-cause-of-gene-hackman-s-wife-s-death-kills-three-in-california/ar-AA1CtcM8 Do you remember the news from December 2024 that talked about vials of Hendra virus, Lyssavirus and Hantavirus that went missing from a lab in Australia? see the following articles: 1. "Deadly virus samples went missing from lab in ‘major biosecurity breach,’ say authorities" source: https://www.foxnews.com/health/deadly-virus-samples-went-missing-lab-major-biosecurity-breach-say-authorities 2. "Hundreds of Vials of Deadly Viruses Missing After Lab Breach" source: https://www.newsweek.com/deadly-virus-missing-laboratory-australia-hantavirus-lyssavirus-hendravirus-1997610 Did you know that vaccines for hantavirus are already being developed? See the following articles: 1. "Progress on the Prevention and Treatment of Hantavirus Disease" The following vaccines are mentioned in "Table 1": - [(Candidate Vaccine: VACV-vectored HTNV (USA)); (Vaccine Type: Virus-vectored recombinant)] - [(Candidate Vaccine: PUUV N, ANDV N, DOBV N (Sweden)); (Vaccine Type: Recombinant N protein)] - [(Candidate Vaccine: DOBV N (Germany)); (Vaccine Type: Recombinant N protein)] - [(Candidate Vaccine: HBcdDOB120, HBcdHTN120, HBcdPUU120 (Germany)); (Vaccine Type: Chimeric core particles)] - [(Candidate Vaccine: Nonreplicating VSV/HTNV pseudotype (Japan)); (Vaccine Type: VSV pseudotype)] - [(Candidate Vaccine: DOBV N, PUUV N (Belgium)); (Vaccine Type: Recombinant N protein)] - [(Candidate Vaccine: Ad-vectored ANDV (USA)); (Vaccine Type: Virus-vectored recombinant)] - [(Candidate Vaccine: VSV-vectored ANDV (USA)); (Vaccine Type: Virus-vectored recombinant)] - [(Candidate Vaccine: HTNV DNA, PUUV DNA (gene gun, USA)); (Vaccine Type: Nucleic acid-based molecular)] - [(Candidate Vaccine: pVAX-LAMP/Gn, pVAX-LAMP/Gc (China)); (Vaccine Type: Nucleic acid-based molecular)] - [(Candidate Vaccine: HFRS Vaccine (China)); (Vaccine Type: Inactivated)] - [(Candidate Vaccine: Hantavax® (Republic of Korea)); (Vaccine Type: Inactivated)] - [(Candidate Vaccine: CD40L and GM-CSF HTNV VLPs (China)); (Vaccine Type: VLP)] - [(Candidate Vaccine: HTNV DNA, PUUV DNA (IM-EP, USA))); (Vaccine Type: Nucleic acid-based molecular)] - [(Candidate Vaccine: HTNV DNA, PUUV DNA (PharmaJet Stratis®, USA)); (Vaccine Type: Nucleic acid-based molecular)] - [(Candidate Vaccine: ANDV DNA (PharmaJet Stratis®, USA)); (Vaccine Type: Nucleic acid-based molecular)] - [(Candidate Vaccine: HTNV DNA, PUUV DNA (IM-EP, ID-EP, USA)); (Vaccine Type: Nucleic acid-based molecular)] Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC6669544/ 2. Clinical trial NCT02116205 titled "Phase 2a Immunogenicity Study of Hantaan/​Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever" Here are a few quotes: Quote 1: "Study Start (Actual) 2014-07-09" Quote 2: "Study Completion (Actual) 2017-07" Source: https://clinicaltrials.gov/study/NCT02116205 3. Clinical trial NCT03682107 titled "Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device" Here are a few quotes: Quote 1: "Study Completion (Actual) 2020-09-23" Quote 2: "This trial is designed to assess the safety, reactogenicity and immunogenicity of an Andes Virus (ANDV) DNA vaccine for the prevention of Hantavirus Pulmonary Syndrome (HPS). ANDV DNA vaccine or placebo will be administered using the PharmaJet Stratis(R) Needle-Free Injection System. The study duration is 23 months while the subject participation duration is 12 months. Subjects assigned to the 3 dose regimen will receive ANDV DNA vaccine on Days 1, 29 and 169, and placebo on Day 57. Source: https://clinicaltrials.gov/study/NCT03682107 4. Clinical trial NCT03718130 titled "Combination HTNV and PUUV DNA Vaccine" Here are a few quotes: Quote 1: "Study Completion (Estimated) 2023-04-30" Quote 2: "The object of DNA vaccination is to deliver DNA into the nuclei of cells capable of presenting the encoded antigen to immune reactive cells that can elicit an immune response." Quote 3: "Subjects will receive one dose of vaccine on each of Days 0, 28, and 56 either intramuscularly or intradermally by electroporation and will be followed until Day 220." Source: https://clinicaltrials.gov/study/NCT03718130 #hantavirus #dnavaccine #nanotechnology #nanoparticle #electroporation #intradermally #intramuscularly #dnaplasmid #needlefreeinjectiondeliverydevice #Hantaanvirus #Puumalavirus #HTNV #PUUV #plandemic #outbreak #bat #April2025 #safeandeffective #agenda2030

View this post on Gab